Hikma’s US Biosimilars Ambitions Begin With $150m Ustekinumab Deal
Firm Signs Commercialization and License Agreement With Bio-Thera Solutions
Hikma told Generics Bulletin earlier this year it was reevaluating the US biosimilars market after witnessing successful launches from several of its rivals. Now the London-based firm has signed an agreement in the US to license and commercialize Bio-Thera Solutions’ Stelara biosimilar candidate.
You may also be interested in...
Hikma has signed another partnership agreement to gain Middle East and North Africa commercialization rights to an ustekinumab biosimilar – although not with its US partner, Bio-Thera Solutions.
China’s Bio-Thera Solutions has revealed the details of its latest clinical trials for proposed biosimilar rivals to Cosentyx (secukinumab) and Nucala (mepolizumab).
Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.